Arcturus Therapeutics Holdings Inc. (ARCT) stock
Close on Nov 11, 2026Market cap $264.62MP/E –Yield –
Arcturus Therapeutics Holdings Inc. saw revenue fall 68.7% to $30.51M over the twelve months to Sep 30, 2026. Free cash flow was -$62.45M. At the latest close the market valued the company at $264.62M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $264.62M
- P/E ratio
- –
- Price to sales
- 8.67
- Price to book
- 1.57
- Dividend yield
- –
- Free cash flow yield
- -23.60%
Fundamentals
- Revenue
- $30.51M
- Net income
- -$87.24M
- EPS, diluted
- -$3.08
- Free cash flow
- -$62.45M
- Book value per share
- $5.93
- Diluted shares
- 28M
Trading
- Next earnings
- Mar 2, 2027 (estimated, after the close)
- Previous close
- $9.39
- Open
- $9.41
- Day's range
- $9.14 – $9.67
- Volume
- 443,226
- Average volume (20 days)
- 715,625
- Index membership
- Russell 2000 (since Jun 2020), Russell 3000 (since Aug 2020)
- Beta (5 years)
- 2.18
- 52-week range
- $5.50 – $17.96
- RSI (14 days)
- 40.9
- Volatility (1 year)
- 82.1%
- Relative volume
- 0.51×
- WACC
- 15.8%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ARCT | S&P 500 | Difference | ARCT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -32.2% | -2.4% | −29.8 pts | ||
| 3 months | +23.8% | -1.2% | +25.0 pts | ||
| Year to date | +51.9% | +12.3% | +39.6 pts | ||
| 1 year | +7.4% | +12.4% | −5.1 pts | ||
| 3 years | -51.4% | +78.8% | −130.2 pts | -21.4% | +21.4% |
| 5 years | -75.1% | +75.2% | −150.3 pts | -24.3% | +11.9% |
| 10 years | -31.4% | +311.1% | −342.5 pts | -3.7% | +15.2% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Arcturus Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Results
About Arcturus Therapeutics
Pharmaceutical Preparations
Arcturus is a biotechnology company that develops messenger RNA medicines and vaccines targeting rare diseases and infectious conditions. The company utilizes proprietary lipid nanoparticle delivery and self-amplifying mRNA platforms to design its products. Its pipeline features KOSTAIVE, an approved self-amplifying mRNA vaccine for COVID-19, alongside therapeutic candidates in clinical evaluation for cystic fibrosis and ornithine transcarbamylase deficiency. Arcturus also advances vaccines against seasonal and pandemic influenza. The company collaborates with pharmaceutical partners, including CSL Seqirus and Meiji Seika Pharma, to commercialize vaccines, and targets patients with rare genetic respiratory and liver disorders.
Company profile, executives and historyArcturus Therapeutics stock: common questions
What is Arcturus Therapeutics's stock price?
ARCT closed at $9.31 on Nov 11, 2026, down 0.85% on the day. Over the past 52 weeks it traded between $5.50 and $17.96.
What is Arcturus Therapeutics's market cap?
Arcturus Therapeutics was worth $264.62M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ARCT's P/E ratio?
Arcturus Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.08), so it has no meaningful P/E ratio.
How much revenue does Arcturus Therapeutics make?
Arcturus Therapeutics reported revenue of $30.51M for the twelve months to Sep 30, 2026, down 68.7% from a year earlier.
Does Arcturus Therapeutics pay a dividend?
No. Arcturus Therapeutics has not paid a cash dividend over the last twelve months.
When does Arcturus Therapeutics report earnings next?
Arcturus Therapeutics is expected to report Q4 FY2026 results on Mar 2, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ARCT stock performed over the past year?
Including dividends, ARCT returned +7.4% over the past year, against +12.4% for the S&P 500.
How many ARCT shares are sold short?
5M shares were sold short at the latest FINRA report, 20.70% of the float, or 7.4 days of average trading volume.
Who are Arcturus Therapeutics's competitors?
Companies most similar to Arcturus Therapeutics by business, industry and size include CAPR, QURE, PRQR, VRDN, WVE.
See a number that looks wrong?